Pacer Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$19.1M Sell
295,524
-641,769
-68% -$45.2M 0.05% 316
2025
Q4
$63.1M Buy
937,293
+458,419
+96% +$30.8M 0.16% 141
2025
Q3
$35.1M Buy
478,874
+456,649
+2,055% +$30.3M 0.09% 222
2025
Q2
$1.16M Buy
22,225
+10,631
+92% +$605K ﹤0.01% 1189
2025
Q1
$740K Sell
11,594
-17,412
-60% -$1.01M ﹤0.01% 1311
2024
Q4
$1.39M Sell
29,006
-255
-0.9% -$13.1K ﹤0.01% 1194
2024
Q3
$1.67M Sell
29,261
-185
-0.6% -$10.6K ﹤0.01% 1076
2024
Q2
$1.54M Buy
29,446
+1,530
+5% +$67.1K ﹤0.01% 1063
2024
Q1
$1.14M Buy
27,916
+1,540
+6% +$57.7K ﹤0.01% 1159
2023
Q4
$975K Buy
26,376
+15,261
+137% +$575K ﹤0.01% 1196
2023
Q3
$425K Sell
11,115
-22,265
-67% -$912K ﹤0.01% 1181
2023
Q2
$1.2M Buy
33,380
+25,080
+302% +$856K ﹤0.01% 972
2023
Q1
$317K Sell
8,300
-17,616
-68% -$826K ﹤0.01% 1251
2022
Q4
$1.47M Buy
25,916
+20,021
+340% +$1.03M 0.01% 650
2022
Q3
$233K Buy
+5,895
New +$261K ﹤0.01% 1568
2022
Q1
Sell
-14,912
Closed -$600K 2393
2021
Q4
$600K Sell
14,912
-4,640
-24% -$173K 0.01% 1465
2021
Q3
$795K Buy
19,552
+5,668
+41% +$237K 0.01% 954
2021
Q2
$630K Sell
13,884
-1,859
-12% -$82.3K 0.01% 1043
2021
Q1
$656K Buy
15,743
+4,165
+36% +$190K 0.01% 950
2020
Q4
$494K Buy
11,578
+6,972
+151% +$251K 0.01% 981
2020
Q3
$121K Buy
+4,606
New +$128K ﹤0.01% 1234
2018
Q4
Sell
-6,765
Closed -$123K 754
2018
Q3
$123K Buy
+6,765
New +$119K ﹤0.01% 1067
2018
Q1
Sell
-2,125
Closed -$43K 1076
2017
Q4
$43K Buy
+2,125
New +$39.1K ﹤0.01% 1032

Other funds holding HALO

Pacer Advisors's HALO Position: Q1 2026 in Review

Pacer Advisors reduced its Halozyme (HALO) stake by 68% in Q1 2026, selling an estimated $45.2M and leaving 295,524 shares worth $19.1M. The position accounts for 0.05% of the portfolio, ranked #316.

Pacer Advisors first reported a position in HALO in Q4 2017 and has held it in 23 quarters since. The position peaked at $63.1M in Q4 2025. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Pacer Advisors held 295,524 shares of Halozyme worth $19.1M as of Q1 2026.
  • Pacer Advisors sold 641,769 Halozyme shares in Q1 2026, an estimated $45.2M.
  • Halozyme made up 0.05% of Pacer Advisors's portfolio in Q1 2026, its #316 holding.
  • Pacer Advisors first reported a position in Halozyme in Q4 2017 and has held it in 23 quarters since.
  • Pacer Advisors's Halozyme position peaked at $63.1M in Q4 2025.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.